Penumbra (PEN) earnings
- Jun 2026
- Dec 2025
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 390 | +14.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 10.5 | −1.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 34.8 | −23.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$322.41 +0.48% · +$1.55
Performance +29.5% 1Y
1Y: $249 on 17 Oct 2025 → $322.41. High $359.4 (27 Jan 2026), low $225.54 (5 Nov 2025).
- Previous close
- $320.86
- 52-week range
- $225.54 – $359.4
- One year
- +30.20%
Overview
- Symbol
- PEN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Financials
What the filings say
Net profit, year on year: −23% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 301 | 316 | 324 | 339 | 355 | 385 | 375 | 390 |
| Operating profit | 35 | 43 | 40 | 41 | 49 | 59 | 38 | 41 |
| Operating margin | 11.8% | 13.6% | 12.4% | 12.0% | 13.8% | 15.4% | 10.2% | 10.5% |
| Other income | 4 | 2 | 4 | 4 | 3 | 4 | 3 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 40 | 44 | 44 | 45 | 52 | 64 | 42 | 46 |
| Tax rate | 25.8% | 24.0% | 10.6% | 0.1% | 12.4% | 25.6% | 21.8% | 24.6% |
| Net profit | 30 | 34 | 39 | 45 | 46 | 47 | 33 | 35 |
| EPS ($ per share) | 0.76 | — | 1.02 | 1.17 | 1.17 | — | 0.83 | 0.88 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 9 | 58 | 41 | 46 | 44 | 135 | 60 | 238 |
| Total liabilities | 93 | 180 | 185 | 290 | 372 | 377 | 382 | 399 |
| Fixed assets | 35 | 52 | 48 | 59 | 65 | 73 | 63 | 117 |
| Total assets | 515 | 666 | 823 | 1,244 | 1,371 | 1,556 | 1,533 | 1,827 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 29 | 27 | -33 | 10 | -56 | 97 | 168 | 239 |
| Cash from investing | -0 | -13 | -104 | -22 | 55 | -16 | 78 | -405 |
| Cash from financing | -10 | -9 | 135 | 1 | 12 | 16 | -87 | 27 |
| Net cash flow | 17 | 5 | -3 | -10 | 10 | 98 | 157 | -138 |
| Capital expenditure | -10 | -22 | -25 | -21 | -19 | -15 | -21 | -64 |
| Free cash flow | 19 | 5 | -58 | -12 | -75 | 82 | 147 | 175 |
PEN revenue by segment
Embolization and Access grew from 32% to 34% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | 68% | 70% | 70% | 68% | 67% | 66% | 68% | 66% | +12.5% |
| Embolization and Access | 32% | — | 30% | 32% | 33% | — | 32% | 34% | +20.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 78% ↑ 3 pt
- Non Us 22%
As PEN cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
66 filings between Nov 4, 2025 and Oct 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$10.92M
25 sales by 5 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 18
- Award — granted as compensation
- 21
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bose Arani | — | $9.06M | Dec 11, 2025 |
| Yuen Maggie | — | $832.5K | Mar 2, 2026 |
| Roberts Johanna | — | $807.1K | Dec 5, 2025 |
| Grewal Harpreet | — | $162.6K | Apr 2, 2026 |
| Wilder Thomas | — | $57.8K | Jan 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Narayan Shruthi President | Tax withheld | 1,367 | $439.1K |
| Sep 15, 2026 | Narayan Shruthi President | Tax withheld | 1,230 | $391.7K |
| Aug 17, 2026 | Narayan Shruthi President | Award | 3,060 | $0 |
| May 19, 2026 | Elsesser Adam CEO | Gift | 77,000 | $0 |
| Apr 2, 2026 | Grewal Harpreet Director | Sale 10b5-1 plan | 100 | $32.8K |
| Mar 15, 2026 | Roberts Johanna EVP, Gen. Counsel & Secretary | Tax withheld | 186 | $62.5K |
| Mar 15, 2026 | Yuen Maggie Chief Financial Officer | Tax withheld | 186 | $62.5K |
| Mar 15, 2026 | Shiu Lambert Chief Accounting Officer | Tax withheld | 150 | $50.4K |
| Mar 15, 2026 | Narayan Shruthi President | Tax withheld | 117 | $39.3K |
| Mar 2, 2026 | Yuen Maggie Chief Financial Officer | Sale 10b5-1 plan | 2,432 | $832.5K |
| Feb 17, 2026 | Roberts Johanna EVP, Gen. Counsel & Secretary | Award | 2,630 | $0 |
| Feb 17, 2026 | Narayan Shruthi President | Award | 2,630 | $0 |
| Feb 17, 2026 | Shiu Lambert Chief Accounting Officer | Award | 2,300 | $0 |
| Feb 17, 2026 | Yuen Maggie Chief Financial Officer | Award | 2,630 | $0 |
| Feb 15, 2026 | Roberts Johanna EVP, Gen. Counsel & Secretary | Tax withheld | 482 | $163.5K |
| Feb 15, 2026 | Narayan Shruthi President | Tax withheld | 705 | $239.2K |
| Feb 15, 2026 | Shiu Lambert Chief Accounting Officer | Tax withheld | 412 | $139.8K |
| Feb 15, 2026 | Yuen Maggie Chief Financial Officer | Tax withheld | 481 | $163.2K |
| Feb 13, 2026 | Grewal Harpreet Director | Award | 589 | $0 |
| Feb 13, 2026 | Roberts Johanna EVP, Gen. Counsel & Secretary | Award | 2,630 | $0 |
| Feb 13, 2026 | O'Rourke Bridget Director | Award | 589 | $0 |
| Feb 13, 2026 | Narayan Shruthi President | Award | 2,630 | $0 |
| Feb 13, 2026 | Bose Arani Director | Award | 589 | $0 |
| Feb 13, 2026 | Shiu Lambert Chief Accounting Officer | Award | 2,300 | $0 |
| Feb 13, 2026 | Yuen Maggie Chief Financial Officer | Award | 2,630 | $0 |
| Feb 13, 2026 | Wilder Thomas Director | Award | 589 | $0 |
| Feb 13, 2026 | Sarna Surbhi Director | Award | 589 | $0 |
| Feb 13, 2026 | Leeds Janet Director | Award | 589 | $0 |
| Jan 15, 2026 | Narayan Shruthi President | Tax withheld | 286 | $100.2K |
| Jan 6, 2026 | Grewal Harpreet Director | Sale 10b5-1 plan | 186 | $58.2K |
| Jan 2, 2026 | Wilder Thomas Director | Sale 10b5-1 plan | 186 | $57.8K |
| Dec 15, 2025 | Yuen Maggie Chief Financial Officer | Tax withheld | 565 | $174.7K |
| Dec 15, 2025 | Shiu Lambert Chief Accounting Officer | Tax withheld | 300 | $92.7K |
| Dec 15, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Tax withheld | 1,130 | $349.3K |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 4,946 | $1.52M |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 2,030 | $619.5K |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 1,895 | $591.6K |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 3,523 | $1.10M |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 2,082 | $646.5K |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 4 | $1.2K |
| Dec 11, 2025 | Bose Arani Director | Sale 10b5-1 plan | 520 | $159.7K |
| Dec 5, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 300 | $90.0K |
| Dec 2, 2025 | Grewal Harpreet Director | Sale 10b5-1 plan | 100 | $29.3K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 10 | $3.0K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 94 | $27.5K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 78 | $23.2K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 80 | $23.7K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 144 | $42.5K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 155 | $45.7K |
| Dec 1, 2025 | Roberts Johanna EVP, Gen. Counsel & Secretary | Sale 10b5-1 plan | 39 | $11.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Penumbra Inc
Free account. Everything above stays public.
Write why you follow Penumbra Inc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading